Carna Biosciences Inc represents a set of core values and a strong corporate philosophy. The company prioritizes innovation, constantly pushing the boundaries of biomedical research and drug discovery. With a focus on delivering cutting-edge solutions, Carna Biosciences is dedicated to developing highly selective kinase inhibitors and providing exceptional scientific expertise to its global clientele. Committed to fostering collaborations and partnerships, Carna Biosciences aims to accelerate the development of transformative therapeutics to address significant unmet medical needs. The company's emphasis on integrity, excellence, and collaboration drives its mission to improve human health and make a meaningful impact in the field of life sciences.

Carna Biosciences Inc is primarily present in the United States and Japan.

Carna Biosciences Inc has achieved several significant milestones. Firstly, the company successfully advanced its lead kinase inhibitor, CP-547,632, into clinical development for the treatment of cancer and inflammatory diseases. Additionally, Carna Biosciences Inc collaborated with multiple pharmaceutical companies to discover and develop novel kinase inhibitors. The company also established a strong portfolio of over 80 proprietary kinase inhibitors, showcasing its research and development capabilities. Moreover, Carna Biosciences Inc expanded its global presence by opening a subsidiary in Cambridge, UK, enhancing its ability to provide innovative solutions in the field of drug discovery.

Carna Biosciences Inc is a renowned biopharmaceutical company known for its comprehensive portfolio of innovative drug discovery solutions. Established in (insert year), Carna Biosciences has a rich history in developing breakthrough therapies to address unmet medical needs. With a focus on kinase biology, the company has become a global leader in kinase-targeted drug discovery. Carna Biosciences' cutting-edge research, state-of-the-art technology, and experienced team have made significant contributions to the pharmaceutical industry, advancing therapeutic interventions for various diseases. Through strategic collaborations and a commitment to scientific excellence, Carna Biosciences continues to drive advancements in personalized medicine for the benefit of patients worldwide.

The main competitors of Carna Biosciences Inc in the market include companies like Merck & Co., Inc., Novartis AG, and Pfizer Inc. These companies are also engaged in the development and commercialization of innovative drugs and therapies. However, Carna Biosciences Inc stands out with its unique focus on kinase drug discovery and development. With its expertise and strong commitment to advancing kinase biology, Carna Biosciences Inc continues to differentiate itself from competitors and create value for its shareholders.

Carna Biosciences Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Carna Biosciences Inc is focused on developing and commercializing innovative kinase inhibitor drugs. As a leading provider of kinase biology expertise, the company utilizes their extensive knowledge and scientific capabilities to discover and develop small molecule drugs that target kinases involved in various diseases. By leveraging their proprietary technological platforms and collaborations with pharmaceutical partners, Carna Biosciences aims to advance the field of kinase biology and contribute to the development of novel therapeutics.

Poměr Carna Biosciences P/E je 2,63.

Koeficient Carna Biosciences tržních hodnot je 1,54.

AlleAktien kvalitní skóre pro Carna Biosciences je 5/10.

očekávané Carna Biosciences obrat je 3,74 mld. JPY.

očekávané Carna Biosciences zisk je 2,19 mld. JPY.

Carna Biosciences Inc is a leading company in the field of drug discovery, based in Kobe, Japan. The company was founded in 2003 by a group of researchers specializing in the discovery and development of new drugs. Carna Biosciences aims to develop highly specific drugs targeting kinase enzymes. Kinase enzymes play an important role in cell signaling. They are crucial for various biological processes, such as cell division and differentiation, as well as the regulation of metabolic processes. Dysfunctions of kinase enzymes can lead to various diseases, including cancer, inflammation, and autoimmune diseases. Carna Biosciences offers a wide range of products and services for drug discovery. The product range includes over 500 different enzymes, including kinase enzymes, phosphatases, proteases, and other drug targets. The enzymes are offered in various forms, from recombinant proteins to cell-free purified enzymes. Carna Biosciences is also a leading provider of drug screening services. The company offers a comprehensive platform for the identification of new drugs, including high-throughput screening and structure-based design. By utilizing these resources, researchers can identify and optimize potential drugs in a short period of time. Additionally, Carna Biosciences has developed several proprietary technologies that can facilitate and enhance drug discovery. The kinase activity measurement technology "KNIME" enables rapid and reliable identification of kinase activity inhibitors. The "SPRINT" technology (Structure-Prediction-Informed NMR and optimization Technology) allows structure-based optimization of drugs to increase their efficacy. Carna Biosciences is divided into various business units, each focused on specific areas of drug discovery. For example, the "Targeted Kinase Inhibitors" division focuses on the development of new drugs against cancer and inflammatory diseases. The "Protein-Protein Interaction Inhibitors" division develops drugs that selectively inhibit the interaction between proteins involved in certain diseases. The "Epigenetic Modulators" division develops drugs for the modulation of epigenetic mechanisms involved in the development of various diseases. Overall, Carna Biosciences' business model is based on the development and commercialization of highly specific drugs targeting specific enzymes and proteins. By providing a wide range of products and services for drug discovery, the company has established a reputation in the research community. Additionally, Carna Biosciences is proud to be a driving force in the development of new technologies and approaches in drug discovery to accelerate the discovery and development of new drugs.

Carna Biosciences vyplácí dividendu ve výši 0 JPY rozdělenou do výplat během roku.

Dividenda pro Carna Biosciences momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Carna Biosciences je JP3220550002.

WKN společnosti Carna Biosciences je A0NHD5.

Ticker společnosti Carna Biosciences je 4572.T.

Během posledních 12 měsíců vyplatila společnost Carna Biosciences dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Carna Biosciences vyplatí dividendu ve výši 0 JPY.

Výnos z dividend společnosti Carna Biosciences aktuálně činí .

Carna Biosciences vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Carna Biosciences vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 JPY. To odpovídá dividendovému výnosu 0 %.

Carna Biosciences je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Carna Biosciences ve výši 0 JPY, zaznamenané 12. 8. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 12. 8. 2024.

Poslední dividendy byly vyplaceny dne 12. 8. 2024.

V roce 2023 společností Carna Biosciences bylo vyplaceno 0 JPY ve formě dividend.

Dividendy společnosti Carna Biosciences jsou vypláceny v JPY.